Detalhe da pesquisa
1.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495879
2.
DESTINY-Breast03 trial: some questions remain - Authors' reply.
Lancet
; 401(10389): 1653-1654, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210117
3.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Nat Med
; 2024 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38825627